ArticleInternational cancer conference journal2025
Metastatic urachal carcinoma treated with trifluridine/tipiracil and bevacizumab: a case report.
Article in International cancer conference journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Urachal Signet Ring Cell Carcinoma: A Clinicopathological Analysis of 28 Cases.Current oncology (Toronto, Ont.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 53-year-old man with a tumorous lesion at the bladder apex was diagnosed with an unresectable urachal carcinoma. After 10 cycles of combined therapy with 5-fluorouracil, leucovorin, and oxaliplatin, a combination of trifluridine/tipiracil and bevacizumab was initiated as second-line chemotherapy. Despite requiring a switch to bevacizumab monotherapy after the sixth cycle due to hematological toxicity, this regimen effectively controlled the disease for 16 cycles. It resulted in a progression-free survival of 17 months. To the best of our knowledge, this is the first report documenting the use of trifluridine/tipiracil and bevacizumab combination therapy for urachal carcinoma. While the observed disease control was notable in this patient, further accumulation of clinical experience and careful evaluation are warranted before generalizing the efficacy of this regimen in this rare malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.